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Abstract
Background: Malaria transmission in most of Latin America can be considered as controlled. In such a scenario,
parameters of baseline immunity to malaria antigens are of specific interest with respect to future malaria
eradication efforts.
Methods: A cross-sectional study was carried out in two indigenous population groups in Amazonas/Venezuela.
Data from the regional malaria documentation system were extracted and participants from the ethnic groups of
the Guahibo (n = 180) and Piaroa (n = 295) were investigated for the presence of Plasmodium parasites and
naturally acquired antibodies to Plasmodium falciparum antigens in serum. The GMZ2 vaccine candidate proteins
MSP3 and GLURP were chosen as serological markers.
Results: The incidence of P. falciparum in both communities was found to be less than 2%, and none of the
participants harboured P. falciparum at the time of the cross-sectional. Nearly a quarter of the participants (111/475;
23,4%) had positive antibody titres to at least one of the antigens. 53/475 participants (11.2%) were positive for
MSP3, and 93/475 participants (19.6%) were positive for GLURP. High positive responses were detected in 36/475
participants (7.6%) and 61/475 participants (12.8%) for MSP3 and GLURP, respectively. Guahibo participants had
significantly higher antibody titres than Piaroa participants.
Conclusions: Considering the low incidence of P. falciparum, submicroscopical infections may explain the
comparatively high anti-P. falciparum antibody concentrations.
Background
To date, malaria is among the top ten causes of death in
low-income countries [1]. In Venezuela, particularly the
southern states of Bolivar and Amazonas are affected by
malaria transmission. However, mortality is insignificant
and malaria can be considered as controlled [2]. Amazo-
nas (180,145 km²) covers an area nearly twice as big as
Portugal and is inhabited by approximately 150,000
persons. Roughly half of the population is of indigenous
origin and - although the absolute number of cases is
low - Amazonas has the highest malaria incidence per
capita in Venezuela (2007: 68.4 cases/1,000 inhabitants).
Overall, the main malaria species is Plasmodium vivax
(ca. 80%) followed by Plasmodium falciparum (ca 20%,
with declining tendency). Plasmodium malariae is only
occasionally detected [3,4].
As drug resistance continues to be a major problem, an
effective malaria vaccine against P. falciparum would be
a powerful tool in the control of malaria [5,6]. The vac-
cine candidate GMZ2 is a fusion protein of P. falciparum
merozoite surface protein 3 (MSP3) and glutamate rich
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I trials as a promising vaccine candidate in Germany and
Africa [7,8]. Antibodies against both antigens have been
shown to provide partial protection in Saimiri sciureus
monkeys [9] and were associated with protection from
human clinical malaria [10]. However, no data are avail-
able in respect to naturally acquired immunity to MSP3
and GLURP from populations of Latin America [11].
This is of interest since a malaria vaccine such as GMZ2
might be used in other continents than Africa where
exposure to P. falciparum is low.
In 2008, a pilot programme for the evaluation of blister-
packed treatment in distinct ethnic groups was initiated.
An initial cross-sectional study was carried out in two
indigenous population groups in order to gain knowledge
about the micro-epidemiology of malaria in the project
area. A second cross-sectional study is planned to close
the project. As serological markers are useful indicators to
measure transmission variations especially in low endemi-
city areas [12], immune responses to MSP3 and GLURP
antigens were investigated as indicators of naturally
acquired immunity to P. falciparum antigens.
Methods
Study population
The study took place in June 2009 in the municipality of
Atures, Amazonas, Venezuela. Three indigenous commu-
nities were visited. They were inhabited by two ethnic
indigenous population groups, the Guahibo (also: Guajibo,
Wahibo, Hiwi, Jivi) and the Piaroa: 1) Platanillal (475 inha-
bitants, Guahibo); 2) Cerro de Oro (60 inhabitants, Gua-
hibo); 3) Paria Grande (463 inhabitants, Piaroa). The
distance between the communities is small (less than 20
km linear distance) and they are comparable with respect
to ecological, geographical and malariological conditions
such as distance to Anopheles breeding sites. The majority
of residences in the communities are non-traditional gov-
ernmental housing projects. The communities of Platanil-
lal and Paria Grande have a health post, each with a
malaria microscopist.
Ethical clearance, informed consent, and treatment
Ethical clearance was obtained from the institutional
ethical committee of the Amazon Center for the Investi-
gation and Control of Tropical Diseases ‘Simón Bolívar’,
Autonomous Service, Puerto Ayacucho, Amazon State,
Venezuela (SACAICET). Residents were informed about
the ideas and procedures of the study, when necessary
with the help of translators. All residents were invited to
take part. Those consenting orally were interviewed and
examined. Individuals with a blood smear positive for
malaria were treated according to the national guidelines
(P. falciparum: artesunate, mefloquine, and primaquine.
P. vivax: chloroquine, primaquine) [13].
Data extraction of the regional malaria documentation
system
Data from the regional malaria documentation system
were extracted. Malaria cases detected in the health
posts of Platanillal and Paria Grande before the study
took place, from January 2003 to May 2009, were
analysed.
Interviews and basic physical examination
Every participant, or the legal guardian, was interviewed
using semi-structured interviews. Translators assisted if
it was necessary, and standardized questions were
phrased with the support of anthropologists. The struc-
tured part of the interviews concerned malaria antece-
dents, possession and use of mosquito nets, general
condition, unspecific symptoms during the last seven
days, and pregnancy. Every participant was examined
physically including a check for splenomegaly and body
temperature.
Smears and serum
Thick blood smears and thin films were taken from
every participant, air-dried and stained for 45 min with
3% Giemsa using standard procedures1 [14]. Slides were
read and re-read by trained professionals of the SACAI-
CET and of the Regional Health Directory in Puerto
Ayacucho. Ten ml of blood was taken from every parti-
cipant into a vacutainer and centrifuged. Serum was
stored at −20°C until further processing.
Recombinant antigens
Recombinant proteins were produced in Escherichia coli
as described elsewhere [15]. The 48 kDa merozoite surface
protein 3 (MSP3) is divided into two major allele types by
sequence polymorphism. The C-terminal region of the
molecule is highly conserved [16]. The 220 kDa gluta-
mate-rich protein (GLURP) contains one non-repeat and
two repeat regions. Both antigens are involved in antibody
dependent cellular inhibition (ADCI) and are used as sub-
units of the GMZ2 fusion protein [17]. For all experiments
the conserved fragments MSP3212-318 and GLURP27-500
were used.
Antibody measurements
Serum antibodies to MSP3 and GLURP were measured
applying a modified version of a quantitative ELISA
[18]. In brief, microtitre plates were coated with anti-
gens in a dilution of 0.5 mg/ml in PBS overnight at 4°C.
After a first washing cycle (3 times) with PBS-T plus 0,5
mol/litre NaCl wells were blocked for one hour with a
dilution of 30 g of defatted milk powder per litre PBS-T.
As standard, after another washing cycle, duplicate rows
were coated with samples, controls and a standard sam-
ple (with quantified high antibody concentration) in
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ple was added in an X-fold serial dilution from 1/20 to
1/327,680. Samples and controls were added in dupli-
cates in dilutions of 1/50 and 1/200. Samples with opti-
cal densities higher than the positive control were
repeated at 1/800. After washing again, plates were incu-
bated with peroxidase conjug a t e dg o a ta n t i - h u m a nI g G
(Caltag, 1/5,000) for one hour, washed, treated with
TMB-One for 15 min in gloomieness until the reaction
was stopped with sulphuric acid. Then absorbance was
read at 450 nm. The standard sample was used to calcu-
late IgG concentration of the other samples in mg/dl.
Pooled serum from 20 individuals, never having lived in
malaria-endemic areas, served as negative control. The
arithmetic mean of negative controls was 0.0746 mg/dl
(SD 0.0396 mg/dl) and 0.092 mg/dl (SD 0.0441 mg/dl)
for MSP3 and GLURP, respectively.
Data capture and analysis
All data were subjected to plausibility, double-entered and
checked for transcription errors in Epidata v3.0
®. Optical
densities (ODs) were averaged and normalized. The cut-
off value for the difference between duplicates was set at
25%. If the difference was higher, the measurement was
repeated. All results were converted to values in mg/dl
using the positive standard serum. Positivity and high
positivity of samples was defined as any OD higher than
the mean of negative controls plus three and five standard
deviations (SD), respectively. Statistical analysis was per-
formed using SPSS 19
® software. T-Tests were run to
screen for significant differences between the variables
subgroups concerning antibody titres, Chi-Square-Tests to
learn about disparities in respect to antibody positivity.
Age in years, sex, self-reported incidence of malaria epi-
sodes during the last 12 months and lifetime, possession
and frequent utilization of mosquito nets and ethnic
affiliation were included in a binary logistic model to pre-
dict anti-MSP3 and anti-GLURP antibody positivity. This
quite conservative model has the advantage to show an
Odds ratio (OR) for each expression of a variable. Further-
more, a linear regression model was performed to expose
the influence of the aforementioned independent variables
on the direct IgG-titre against the GMZ2-subunits.To do
so, antibody levels had to be transformed to their decadic
logarithm to gain Gaussian distribution. The resulting
model was then de-logarithmized to show comparable and
comprehensible results.
Results
Study population
Four hundred and seventy-five persons participated in
the study. Demographic data of participants and ques-
tionnaire results are summarized in Table 1.
Malaria infections in the two indigenous communities
from 2003 to 2008
Platanillal
Within the six years preceding the cross-sectional study
(2003 - 2008), the health post of Platanillal reported 573
cases of malaria in Guahibo patients (2003: 134 cases;
2004: 62 cases; 2005: 90 cases; 2006: 141 cases; 2007: 95
cases; 2008: 51 cases).
Paria grande
The health post of Paria Grande reported 270 cases of
malaria in Piaroa patients within the six years preceding
the cross-sectional study (2003: 11 cases; 2004: 65 cases;
2005: 29 cases; 2006: 70 cases; 2007: 74 cases; 2008: 21
cases). Of these, 45/573 cases (7.8%) and 36/270 cases
(13.3%) were caused by P. falciparum in Platanillal and
Paria Grande, respectively. All other infections were
caused by P. vivax. P. malariae was not detected.
Malaria infections in the two indigenous communities
from january 2009 to may 2009
Platanillal
Within the five months preceding the cross-sectional
study (January 2009-May 2009), 154 slides were taken in
the health post of Platanillal; 43/154 slides (27.9%) were
positive for P. vivax, and 5/154 slides (3.2%) were posi-
tive for P. falciparum.
Paria grande
Within the five months preceding the cross-sectional
study, 148 slides were taken in the health post of Paria
Grande; 15/148 slides (10.1%) were positive for P. vivax,
and none (0%) was positive for P. falciparum.
Clinical results
Participants (n = 475) complained about the following
symptoms within the preceding seven days: headache
(71; 14,9%), body ache (45; 9,5%), flu-like symptoms
(101; 21,3%), cough (34; 7,2%), chills (5; 1,1%), fever (28;
5,9%), diarrhoea (46; 9,7%), abdominal pain (30, 6,3%),
nausea (34, 7,2%), fatigue (14, 2,9%). The mean tempera-
ture of all participants was 37,02°C (Min. 35,8°C, Max.
38,9°C, SD. 0,4803). 9/475 participants (1.9%) had a
body temperature over 38°C. None of the participants
Table 1 Demographic data of participants and
questionnaire results
Guahibo
(n = 180)
Piaroa
(n = 295)
Age (years, SD) 20,8 (SD 19,1) 22,4 (SD 16,8)
Sex (female) 108 (60%) 147 (49,8%)
Possession of mosquito net 143 (79,4%) 285 (96,6%)
Constant use of mosquito net 125 (69,4%) 263 (89,2%)
Malaria episode in last 12
months
32 (17,8%) 36 (12,2%)
Malaria episode ever 112 (62,2%) 170 (57,6%)
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pants was found positive for P. falciparum at the day of
the cross-sectional study. Two participants (2/475; 0.4%)
were found positive for P. vivax (both <100 parasites/
μl). Both patients were from the Guahibo ethnic group
and reported malaria antecedents. One patient was a
12-year-old anaemic boy (Hb 12.5 mg/dl) in reduced
general condition and with normal body temperature
(36.5°C) reporting chills during the last seven days. The
other patient was a 26-year-old anaemic pregnant
woman (Hb 9.7 mg/dl) with normal body temperature
(37.1°C) complaining about a reduced general state of
health.
Antibodies to MSP3 and GLURP
The cut-off value for a positive sample was set at 0.193
mg/dl and at 0.224 mg/dl for MSP3 and GLURP,
respectively. 111/475 participants (23.4%) were positive
for at least one of the antibodies. 53/475 participants
(11.2%) were positive for MSP3, and 93/475 participants
(19.6%) were positive for GLURP. 35/475 participants
(7.4%) had positive antibody levels against both antigens.
The average value (geometric mean) of positive samples
was 0.36 mg/dl (95% CI 0.32 mg/dl - 0.41 mg/dl) and
0.47 mg/dl (95% CI 0.41 mg/dl - 0.55 mg/dl) for MSP3
and GLURP, respectively. The cut-off value for a high-
positive sample was set at 0.27 mg/dl and at 0.31 mg/dl
for MSP3 and GLURP, respectively. 78/475 participants
(16.4%) were high-positive for at least one of the antibo-
dies. 36/475 participants (7.6%) were high-positive for
MSP3, and 61/475 participants (12.8%) were high-posi-
tive for GLURP. 19/475 participants (4%) had high-posi-
tive antibody levels for both antigens. The highest titres
measured were 2.8 mg/dl and 3.36 mg/dl for MSP3 and
GLURP, respectively.
Stratification for age and sex
Antibody titres were significantly increasing with age
(Spearman Rank Test, RSpGLURP = 0.130, p = 0.005.
RSpMSP3 = 0.259, p < 0.001). When the study population
was grouped by age - each group with a span of 10 years -
a significantly higher number of positives and high-posi-
tives was seen in the older age groups (ANOVA: positives:
pMSP3 < 0.001, pGLURP =0 . 0 0 1 ,h i g h - p o s i t i v e s :p MSP3 <
0.001, pGLURP = 0.028). No significant differences in anti-
body titres or positivity rates were found regarding the sex
of the persons (T-test: pGLURP = 0.101, pMSP3 = 0.169, Chi-
square: pGLURP = 0.101, pMSP3 = 0.184).
Stratification for possession and use of mosquito nets
Comparing possessors (428/475, 90.1%) and non-posses-
sors (47/475, 9.9%) of mosquito nets, holders were found
to have lower levels of GLURP (T-test, pGLURP <0 . 0 0 1 ) ,
but there was no significant difference respective to MSP3
(T-test, pMSP3 = 0.489). Participants who reported daily
use of mosquito nets during the previous 30 nights were
defined frequent users. 392/475 participants (82.5%) were
found to be frequent users. No significant difference in
antibody titres nor positivity rates were found between fre-
quent users and the rest of the study population (T-test,
pGLURP = 0.125, pMSP3 = 0.991; Chi-square-test, pGLURP =
0.182, pMSP3 = 0.084).
Stratification for self-reported malaria episodes
282/475 participants (59.4%) stated they had at least one
malaria episode in their life, and 85/475 (17.9%) reported
a malaria episode during the previous 12 months. Those
who reported to have suffered malaria at least once in
their life showed significantly higher IgG-levels than the
group reporting no previous malaria episode. This differ-
ence was significant for MSP3 (T-test, pMSP3 =0 . 0 3 2 ) ,
but not for GLURP (T-test, pGLURP = 0.062). Those who
stated a malaria episode within the previous 12 months
had slightly more positive responses against both anti-
gens. This difference was significant for GLURP and for
MSP3 (Chi-square, pGLURP = 0.002; pMSP3 < 0.001).
Stratification for ethnic origin
Participants from the ethnic Guahibo group displayed
significantly higher antibody titres and positivity rates
for both antigens when compared to the ethnic Piaroa
group (Table 2).
Binary logistic and linear regression model
The above-mentioned parameters were included in a bin-
ary logistic and a linear regression model to predict posi-
tivity and titres of antibodies against MSP3 and GLURP.
In the binary logistic model, the parameters age, posses-
sion of mosquito nets, and ethnic origin had a significant
outcome: For every year of age, risk of positivity raised
with an OR of 1.03 for both MSP3 (CI: 1.018; 1.051, p < =
0.001) and GLURP (CI: 1.020; 1.049, p < = 0.001). Non-
possession of a mosquito net increased the chance to have
GLURP by 4.05-fold (CI: 1.258; 13.014, p < = 0.001). Gua-
hibo individuals had a 8.04-fold (CI: 4.061; 15.898, p < =
0.001) chance for MSP3 antibody positivity compared to
Piaroa individuals. With respect to GLURP, the chance for
positivity was 2.81-fold higher for Guahibo in comparison
Table 2 Antibody titres and positivity rates in Guahibo and Piaroa participants
Guahibo (n = 180) Piaroa (n = 295)
mg/dl (95% CI) Pos (%) mg/dl (95%) Pos (%)
MSP3 0.07
1 (0.06-0,09) 44
2 (24,4%) 0.05
1 (0.05-0.08) 9
2 (3.1%)
GLURP 0.10
3 (0.09-0.13) 54
4 (30%) 0.07
3 (0.07-0.08) 39
4 (13.2%)
1 T-test, p = 0.001;
2 Chi-square, p < 0.001;
3 T
-test, p = 0.002;
4 Chi-square, pGLURP < 0.001
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of the linear regression model are shown in Table 3.
Discussion
Results show that the two GMZ2 antigens are recognized
by antibodies acquired through natural infections in the
Venezuelan Amazon. Overall, the results correspond -
except high responders - to rather low responses which
are roughly two-fold higher than the cut-off value for
positives. As antibody subclasses are of great importance
[19] further studies on IG-subclasses have to show
whether functional antibodies are acquired through nat-
ural exposure. The question if a GMZ2 vaccine would be
effective in this area remains open, because antibodies
stimulated by vaccines do not automatically protect as do
naturally acquired antibodies [20]. In respecto to vaccine
efficacy, only clinical trials with disease as endpoint can
prove the impact of a vaccine.
The two main findings of this study were 1) the high
prevalence of antibodies against conserved parts of
MSP3 and GLURP antigens in the two population
groups with low incidence of P. falciparum malaria, and
2) the significantly higher prevalence of MSP3 and
GLURP antibodies in the Guahibo group when com-
pared to the Piaroa group.
The total population of the Piaroa is about 12,000 per-
sons. Anthropologists describe them as peaceful and
egalitarian. Traditionally, the Piaroa’s agroforestal subsis-
tence strategy implicated small, dispersed and mobile
ways of settlement in groups of about 50 individuals.
Nowadays they are living in bigger communities mostly
built by the Venezuelan government in the periphery of
their ancestral territories, which they still use as crop-
land and hunting grounds [21].
The Guahibo consist of about 30,000 persons settling
mainly around Puerto Ayacucho and neighbouring
Colombian areas. As a patriarchal society, great impor-
tance is placed on the nuclear family. Traditionally, they
inhabited vast flatlands in Colombia and Venezuela as
nomadic foragers. Nowadays, they inhabit communities
constructed by the Venezuelan government. They are
mainly assimilated according to language and clothing
style, but still are threatened by pauperisation [22].
The serological results of this study confirm previous
investigations hinting to an elevated risk for malaria in
the Guahibo population [2,23]. Living conditions, socioe-
conomic parameters, adherence to medicaments, confi-
dence in the health system, and cultural habits may
explain the different transmission levels in the two ethnic
groups under study. Different immune responses with
different protection patterns in genetically different
populations are also a possible factor [24,25]. Further
research involving multidisplinary expertise as well as
members of the communities should focus on this “hot
spot” of malaria transmission in the Venezuelan Amazon.
The positive correlation of antibody titeres and preva-
lences with age has been known for a long time [26].
When people live in an area endemic for malaria the
chances of contact with the antigen raise with the years,
and so do antibody titres and prevalences. Similarly, the
chances of contact decrease with the use of mosquito nets.
Such, as shown in other studies [27], a difference in
GLURP antibody titres and prevalences could be observed
between mosquito net users and non-users.
This cross-sectional study evaluated immune responses
against two blood stage antigens considered as promising
vaccine candidates on the basis of studies carried out in
completely different settings. Samples were taken in the
period of low transmission when the direct contact with
P. falciparum parasites is expected to be minimal. Indeed,
only two persons in nearly half a thousand participants
were found harbouring parasites (2/475; 0.4%). Both
Table 3 Linear regression model
MSP3 GLURP
b 95% low CI for b high p b 95% low CI for b high p
Age in years 1,02 1,01 1,02 <0.001 1,01 1,00 1,01 0.019
Sex 1,07 0,92 1,26 0.373 1,10 0,90 1,36 0.354
Possession mosquito net 1,12 0,77 1,63 0.556 2,52 1,54 4,13 <0.001
Constant use of ITN
1 1,18 0,89 1,56 0.256 1,30 0,90 1,88 0.168
Malaria episode (ever) 1,10 0,92 1,32 0.309 0,99 0,78 1,26 0.947
Malaria episode (12 m
2) 1,37 1,08 1,73 0.009 1,34 0,98 1,82 0.066
Ethnic group 1,31 1,10 1,54 0.002 1,26 1,01 1,57 0.041
Explanation: As antibody titres are not expected to be Gaussian distributed the models calculated with the decadic logarithms of the measured IgG levels.
Results were then delogarithmized. Age in years showed significant influence for each year of age. Females’ trend to have higher antibody levels resulted not
statistically significant. The possession of a mosquito net caused no significant coefficient for MSP3, but for GLURP, whereas every night usage of a mosquito-net
during the last 30 days entailed no significant influence antibodies. The coefficients for self-reported malaria episodes during the whole lifetime were not
significant, unlike those for the incidence in the previous 12 months (MSP3). Ethnic background affected the linear equation with significant coefficients for both,
MSP3 and GLURP
1 Insecticide treated net
2 Within the last 12 months
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P. falciparum. Nevertheless, nearly a quarter of partici-
pants had antibodies to at least one of both antigens. As
adding up immune responses to individual antigens
might not be an appropriate procedure for results, which
show - not surprisingly for outbred human populations -
an extensive variation between individuals, it is important
to note that 7.6% and 12,8% of participants had high anti-
body titres against MSP3 and GLURP, respectively. Possi-
bly only high-positive antibody responses are relevant
and/or specific results in this endemic area. Moreover, it
should be taken into account that higher antibody
responses might persist longer than lower ones.
Using the records of the health information system of
Amazonas the level of malaria transmission in the com-
munities during the years and months before the study
was approximated. As the health posts of Platanillal and
P a r i aG r a n d ew e r ec o m p a r a b l ei nt h ev o l u m eo fs l i d e s
taken per year (e.g. 2009: Platanillal, 280 slides; Paria
Grande, 269 slides) and data of ethnic origin, origin of
infection, and population census were available, the pre-
valence in both communities could be estimated for
malaria in general, and for P. falciparum in particular.
The average pan-malarial incidence was higher in the
Guahibo population of Platanillal (ca 1 8 % )t h a ni nt h e
Piaroa population of Paria Grande (ca 8%). However, this
was due to P. vivax infections, whereas the transmission
of P. falciparum was surprisingly low in both population
groups. Within a time period of 6.5 years, only 50 and 36
cases of P. falciparum were detected in Guahibo and
Piaroa people of the health posts of Platanillal and Paria
Grande, respectively, and the average incidence of P. fal-
ciparum was estimated to be less than two percent in
both population groups, without a significant difference.
MSP3 and GLURP antibodies last six-12 months if no
boost infection takes place [8]. In order to explain the
phenomenon that antibodies were detected in more
individuals than expected, submicroscopical infections
must be considered as an influencing variable. The use
of other antigens (for example, pre-erythrocytic anti-
g e n s )m i g h th a v el e dt oo t h e rr e s u l t s ,y e ti tc a nb e
assumed that conclusions would have differed slightly
only. This is in line with previous investigations demon-
strating asymptomatic carriers in this area [28]; interest-
ingly, more than 20% of those who denied they ever
suffered from any type of malaria had positive IgG titres.
Another - yet to be proven - hypothesis would be the
polyclonal activation of effector T killer cells and mem-
ory B-cells against P. falciparum antigens by P. vivax
[29].
Controlled malaria is the result of an interplay of host
defense systems, public health measures, ambiental con-
ditions, behavioural features, and epidemiology and
infection biology of the parasite. Interventions should be
weighed carefully in order not to destabilize an estab-
lished equilibrium. The epidemiology and immunology
of controlled malaria might be subject of growing inter-
est for malariologists and decision makers, as lessons
learnt in low endemic areas could be instructive after
eradication and control efforts have been successful in
high endemic areas.
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